


CLAIMS

What is claimed is:

- 5 1. A compound of Formula (I)



(I)

10 wherein:

R^1 is phenyl, pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl, and is unsubstituted or substituted with 1-2 substituents selected from the group consisting of
 15 halogen, C_{1-6} alkyl, trifluoromethyl, C_{1-6} alkoxy, trifluoromethoxy, and cyano;

R^2 is independently hydrogen or C_{1-6} alkyl;

20 R^3 is selected from the group consisting of isopropyl, tert-butyl, sec-butyl, and $\text{C}(\text{CH}_3)_2\text{SCH}_3$;

R^4 is phenyl, indazolyl, benzothiazolyl, quinolinyl, quinoxalinyl, 2,3-dihydrobenzofuranyl, or
 25 1,3-benzodioxolyl, and is unsubstituted or substituted with 1-2 substituents selected from the group consisting

of amino, acetamido, halo, C₁₋₆alkyl, trifluoromethyl, C₁₋₆alkoxy, trifluoromethoxy, and cyano;

m is independently selected from 0, 1, 2, or 3; and

5

n is 1 or 2;

or a pharmaceutically acceptable salt thereof.

10 2. A compound of claim 1 wherein R¹ is phenyl, 3-fluorophenyl, 4-fluorophenyl, 3,5-difluorophenyl, 2,4-difluorophenyl, 2,6-difluorophenyl, 3-trifluoromethylphenyl, 3-pyridinyl, or 3-methoxyphenyl.

15 3. A compound of claim 2 where R¹ is phenyl, 3-fluorophenyl, 4-fluorophenyl, 3,5-difluorophenyl, or 3-methoxyphenyl.

4. A compound of claim 1 where R² is hydrogen or
20 methyl.

5. A compound according to Claim 1 wherein R⁴ is selected from the group consisting of 4-aminophenyl, 3-aminophenyl, 3-amino-4-methylphenyl, 4-methoxyphenyl, 25 6-benzothiazolyl, 2-amino-6-benzothiazolyl, 2-acetamido-6-benzothiazolyl, 2-methyl-6-benzothiazolyl, 7-benzothiazolyl, 2-amino-7-benzothiazolyl, 2-acetamido-7-benzothiazolyl, 2-methyl-7-benzothiazolyl, 2,3-dihydrobenzofuran-5-yl, 2,3-benzodioxl-5-yl, 6- 30 indazolyl, 6-quinolinyl, and 6-quinoxaliny.


6. The compound according to Claim 5 wherein R^4 is selected from 4-aminophenyl, 6-indazolyl, 6-benzothiazolyl, 2-amino-6-benzothiazolyl, 6-quinolinyl, and 4-methyl-3-aminophenyl.

5

7. A compound according to Claim 1 wherein m is 0.


8. A compound according to Claim 1 wherein n is 1.







10 9. A compound of claim 1 according to Formula Ia.










Ia

15 10. A compound of Claim 1 selected from the group consisting of












;




;




;




;



;



;



or a pharmaceutically acceptable salt thereof.

5

11. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 and a pharmaceutically acceptable carrier.

10 12. A method for inhibiting HIV protease comprising administering a therapeutically effective amount of a compound of Claim 1 to a patient in need of such treatment.

15 13. A method for treating HIV infection comprising administering a therapeutically effective amount of a compound of Claim 1 to a patient in need of such treatment.

20 14. The method of claim 13 comprising co-administering a therapeutic amount of an HIV reverse transcriptase inhibitor, an HIV protease inhibitor, or a combination thereof.

15. A method for treating AIDS or ARC comprising administering a therapeutically effective amount of a compound of Claim 1 to a patient in need of such treatment.

5

16. The method of claim 15 comprising co-administering a therapeutic amount of an HIV reverse transcriptase inhibitor, an HIV protease inhibitor, or a combination thereof.